Loxo Oncology Announces Details of Two Larotrectinib Clinical Data Oral Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

May 17, 2017

STAMFORD, Conn., May 17, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that study investigators will present larotrectinib (LOXO-101) interim clinical data across the RECIST-evaluable TRK fusion clinical trial database from all three ongoing clinical trials in a late breaking oral presentation at the ASCO Annual Meeting being held on June 2 - 6, 2017 in Chicago, IL. This presentation was also selected for inclusion in the ASCO Press Program. In addition, the larotrectinib interim pediatric Phase I clinical data will be highlighted in a separate oral presentation.

The schedule for the presentations is as follows:

**Late Breaking Presentation Date & Time:** Saturday, June 3, 2017, 1:15 – 4:15PM CT
**Title:** The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.
**Abstract Number:** LBA2501
**Session Title:** Developmental Therapeutics – Clinical Pharmacology and Experimental Therapeutics
**Location:** E450ab
**Presenter:** David Michael Hyman, M.D.

**Presentation Date & Time:** Monday, June 5, 2017, 8:00 – 11:00AM CT
**Title:** A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.
**Abstract Number:** 10510
**Session Title:** Pediatric Oncology II
**Location:** S504
**Presenter:** Theodore Willis Laetsch, M.D.

**Conference Call and Webcast Information**
Loxo Oncology will host a conference call and live webcast with slides and Q&A on Sunday, June 4, 2017 at 5:30PM CT to discuss the larotrectinib data presented at ASCO. To participate in the conference call, please dial (877) 930-8065 or (253) 336-8041 and refer to 14447513. A live webcast of the presentation will be available at http://ir.loxooncology.com/. A replay of the webcast will be available shortly after the conclusion of the call and archived on the company’s website for 90 days following the call.

**About Larotrectinib (LOXO-101)**
Larotrectinib (LOXO-101) is a potent, oral and selective investigational new drug in clinical development for the treatment of patients with cancers that harbor abnormalities involving the tropomyosin receptor kinases (TRKs). Growing research suggests that the NTRK genes, which encode for TRKs, can become abnormally fused to other genes, resulting in growth
signals that can lead to cancer in many sites of the body. In an ongoing Phase 1 clinical trial, larotrectinib has demonstrated encouraging preliminary efficacy. Larotrectinib is also being evaluated in the NAVIGATE global Phase 2 multi-center basket trial in patients with solid tumors that harbor TRK gene fusions, and the SCOUT Phase 1/2 trial in pediatric patients, including patients with advanced cancer, TRK gene fusions and infantile fibrosarcoma. Larotrectinib has been granted Breakthrough Therapy Designation and Rare Pediatric Disease Designation by the U.S. FDA. For additional information about the larotrectinib clinical trials, please refer to www.clinicaltrials.gov. Interested patients and physicians can contact the Loxo Oncology Physician and Patient Clinical Trial Hotline at 1-855-NTRK-123 or visit www.loxooncologytrials.com.

About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company’s website at www.loxooncology.com.

Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
jake@loxooncology.com

Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
prahmer@troutgroup.com

Media:
Dan Budwick
1AB Media
973-271-6085
dan@1abmedia.com